Abstract
AbstractThe identification of metabolites allows for the expansion of possible targets for anti-doping analysis. Especially for novel substances such as selective androgen receptor modulators (SARMs), information on metabolic fate is scarce. Novel approaches such as the organ on a chip technology may provide a metabolic profile that resembles human in vivo samples more closely than approaches that rely on human liver fractions only. In this study, the SARM RAD140 was metabolized by means of subcellular human liver fractions, human liver spheroids in an organ on a chip platform, and electrochemical (EC) conversion. The resulting metabolites were analyzed with LC-HRMS/MS and compared to a human doping control urine sample that yielded an adverse analytical finding for RAD140. A total of 16 metabolites were detected in urine, while 14, 13, and 7 metabolites were detected in samples obtained from the organ on a chip experiment, the subcellular liver fraction, and EC experiments, respectively. All tested techniques resulted in the detection of RAD140 metabolites. In the organ on a chip samples, the highest number of metabolites were detected. The subcellular liver fractions and organ on a chip techniques are deemed complementary to predict metabolites of RAD140, as both techniques produce distinct metabolites that are also found in an anonymized human in vivo urine sample.
Graphical abstract
Funder
Bundesministerium des Innern, für Bau und Heimat
Manfred-Donike Institute for Doping Analysis e.V.
Ministry for Culture and Science North Rhine-Westphalia
Deutsche Sporthochschule Köln (DSHS)
Publisher
Springer Science and Business Media LLC
Subject
Biochemistry,Analytical Chemistry
Reference42 articles.
1. Miller CP, Shomali M, Lyttle CR, O’Dea LSL, Herendeen H, Gallacher K, et al. Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140. ACS Med Chem Lett. 2011;2(2):124–9. https://doi.org/10.1021/ml1002508.
2. LoRusso P, Hamilton E, Ma C, Vidula N, Bagley RG, Troy S, et al. A first-in-human phase 1 study of a novel selective androgen receptor modulator (SARM), RAD140, in ER+/HER2- metastatic breast cancer. Clin Breast Cancer. 2022;22(1):67–77. https://doi.org/10.1016/j.clbc.2021.08.003.
3. Thevis M, Piper T, Beuck S, Geyer H, Schänzer W. Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105. Rapid Commun Mass Spectrom. 2013;27(11):1173–82. https://doi.org/10.1002/rcm.6558.
4. Sobolevsky T, Dikunets M, Rodchenkov G. In vitro and in vivo metabolism of RAD140, a novel non-steroidal SARM. Recent Advances In Doping Analysis (21). 2013:121–4.
5. World Anti-Doping Agency. 2016 Anti-doping testing figures https://www.wada-ama.org/sites/default/files/resources/files/2016_anti-doping_testing_figures.pdf. Accessed 27.04.2023
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献